
Annual report 2022
added 12-21-2024
Genetron Holdings Limited Retained Earnings 2011-2026 | GTH
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings Genetron Holdings Limited
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | -4.94 B | -1.84 B | -1.17 B | -703 M | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -703 M | -4.94 B | -2.16 B |
Quarterly Retained Earnings Genetron Holdings Limited
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -5.44 B | - | - | - | -4.94 B | - | - | - | -1.84 B | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in CNY currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -1.84 B | -5.44 B | -4.07 B |
Retained Earnings of other stocks in the Diagnostics research industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-62.9 M | - | -6.23 % | $ 30.6 M | ||
|
Akumin
AKU
|
-280 M | - | -17.87 % | $ 25.9 M | ||
|
Anixa Biosciences
ANIX
|
-252 M | $ 3.03 | -2.26 % | $ 98.3 K | ||
|
Aspira Women's Health
AWH
|
-499 M | - | -6.19 % | $ 10.5 M | ||
|
Brainsway Ltd.
BWAY
|
-77.3 M | $ 23.35 | -2.91 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
-2.23 B | $ 34.5 | 2.16 % | $ 371 M | ||
|
Biocept
BIOC
|
-298 M | - | -13.05 % | $ 7.29 M | ||
|
Accelerate Diagnostics
AXDX
|
-607 M | - | -61.36 % | $ 2.46 M | ||
|
BioNano Genomics
BNGO
|
-693 M | $ 1.29 | -12.26 % | $ 1.64 M | ||
|
Check-Cap Ltd.
CHEK
|
-170 M | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-84 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
-154 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
4.6 M | - | - | $ 79.8 M | ||
|
Castle Biosciences
CSTL
|
-200 M | $ 39.74 | 1.48 % | $ 1.1 B | ||
|
Danaher Corporation
DHR
|
44.2 B | $ 219.29 | -0.08 % | $ 160 B | ||
|
DermTech
DMTK
|
-424 M | - | -11.32 % | $ 2.94 M | ||
|
Global Cord Blood Corporation
CO
|
2.89 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-624 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-150 M | - | - | $ 7.1 B | ||
|
PRA Health Sciences, Inc.
PRAH
|
440 M | - | - | $ 10.7 B | ||
|
DexCom
DXCM
|
1.02 B | $ 73.31 | -0.93 % | $ 28.3 B | ||
|
CareDx, Inc
CDNA
|
-678 M | $ 20.55 | -1.23 % | $ 1.1 B | ||
|
Celcuity
CELC
|
-272 M | $ 109.48 | -2.35 % | $ 4.32 B | ||
|
Exact Sciences Corporation
EXAS
|
-4.5 B | $ 102.41 | 0.1 % | $ 19 B | ||
|
DarioHealth Corp.
DRIO
|
-349 M | $ 10.2 | -0.97 % | $ 289 M | ||
|
Enzo Biochem
ENZ
|
-294 M | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
590 M | $ 26.19 | -0.19 % | $ 792 M | ||
|
Guardant Health
GH
|
-2.58 B | $ 113.17 | 2.43 % | $ 13.9 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-230 M | - | -20.0 % | $ 1.06 M | ||
|
Heska Corporation
HSKA
|
-169 M | - | - | $ 1.31 B | ||
|
IDEXX Laboratories
IDXX
|
5.33 B | $ 672.84 | -0.57 % | $ 55.5 B | ||
|
Illumina
ILMN
|
-1.24 B | $ 144.81 | -3.26 % | $ 23 B | ||
|
QIAGEN N.V.
QGEN
|
2.45 B | - | - | $ 10.6 B | ||
|
IQVIA Holdings
IQV
|
6.06 B | $ 230.33 | -2.19 % | $ 41.8 B | ||
|
Charles River Laboratories International
CRL
|
1.81 B | $ 210.51 | -0.59 % | $ 10.8 B | ||
|
Lantheus Holdings
LNTH
|
446 M | $ 66.91 | 0.34 % | $ 4.63 B | ||
|
Quest Diagnostics Incorporated
DGX
|
9.36 B | $ 186.45 | 2.27 % | $ 20.7 B | ||
|
Biodesix
BDSX
|
-462 M | $ 10.11 | 4.66 % | $ 1.31 B | ||
|
Precipio
PRPO
|
-98.2 M | $ 24.07 | -0.78 % | $ 31.2 M | ||
|
Laboratory Corporation of America Holdings
LH
|
8.3 B | $ 271.34 | 0.56 % | $ 22.8 B | ||
|
ICON Public Limited Company
ICLR
|
2.72 B | $ 181.44 | -2.39 % | $ 15 B | ||
|
Medpace Holdings
MEDP
|
8.17 M | $ 582.66 | -1.76 % | $ 18 B | ||
|
Agilent Technologies
A
|
348 M | $ 133.33 | 0.07 % | $ 40.5 B | ||
|
Biomerica
BMRA
|
-53.2 M | $ 2.41 | 0.84 % | $ 5.54 M | ||
|
OpGen
OPGN
|
-294 M | - | -16.95 % | $ 1.54 M | ||
|
Bioventus
BVS
|
-322 M | $ 7.86 | 0.51 % | $ 492 M | ||
|
Quidel Corporation
QDEL
|
945 M | $ 27.24 | -0.62 % | $ 1.15 B | ||
|
Motus GI Holdings
MOTS
|
-154 M | - | -34.28 % | $ 263 K |